Management of Diffuse Low-Grade Glioma: The Renaissance of Robust Evidence

The surgical management of diffuse low-grade gliomas (DLGGs) has undergone a paradigm shift toward striving for maximal safe resection when feasible. While extensive observational data supports this transition, unbiased evidence in the form of high quality randomized-controlled trials (RCTs) is lacking. Furthermore, despite a high volume of molecular, genetic, and imaging data, the field of neuro-oncology lacks personalized care algorithms for individuals with DLGGs based on a robust foundation of evidence. In this manuscript, we (1) discuss the logistical and philosophical challenges hindering the development of surgical RCTs for DLGGs, (2) highlight the potential impact of well-designed international prospective observational registries, (3) discuss ways in which cutting-edge computational techniques can be harnessed to generate maximal insight from high volumes of multi-faceted data, and (4) outline a comprehensive plan of action that will enable a multi-disciplinary approach to future DLGG management, integrating advances in clinical medicine, basic molecular research and large-scale data mining.

[1]  C. Romanowski,et al.  'Low grade glioma': an update for radiologists. , 2017, The British journal of radiology.

[2]  M. Kris,et al.  Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment , 2017, JAMA.

[3]  C. Bettegowda,et al.  Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms. , 2017, The Journal of molecular diagnostics : JMD.

[4]  W. Mason,et al.  Neurosurgical management of adult diffuse low grade gliomas in Canada: a multi-center survey , 2015, Journal of Neuro-Oncology.

[5]  D. Moher,et al.  Improving the reporting of pragmatic trials: an extension of the CONSORT statement , 2008, BMJ : British Medical Journal.

[6]  Jirí Sedlár,et al.  Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence , 2017, Journal of Digital Imaging.

[7]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[8]  B. Preston,et al.  Case Series , 2010, Toxicologic pathology.

[9]  B. Knoppers.  Broaden human-rights focus for health data under GDPR , 2018, Nature.

[10]  David S. Wishart,et al.  Applications of Machine Learning in Cancer Prediction and Prognosis , 2006, Cancer informatics.

[11]  V. Haughton,et al.  Functional MR imaging: paradigms for clinical preoperative mapping. , 2003, Magnetic resonance imaging clinics of North America.

[12]  David Moher,et al.  Reporting guidelines for clinical trials evaluating artificial intelligence interventions are needed , 2019, Nature Medicine.

[13]  K. Hoang-Xuan,et al.  The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033 , 2018, Acta Neuropathologica.

[14]  B. Scheithauer,et al.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[16]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[17]  M. Berger,et al.  Management of low-grade glioma: a systematic review and meta-analysis. , 2018, Neuro-oncology practice.

[18]  A. Twijnstra,et al.  Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Ohno-Machado,et al.  Patient Perspectives About Decisions to Share Medical Data and Biospecimens for Research , 2019, JAMA network open.

[20]  Hugues Duffau,et al.  Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection. Clinical article. , 2011, Journal of neurosurgery.

[21]  Matthew C Tate,et al.  Probabilistic map of critical functional regions of the human cerebral cortex: Broca's area revisited. , 2014, Brain : a journal of neurology.

[22]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[23]  M. J. van den Bent,et al.  The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis , 2017, Neuro-oncology.

[24]  Geirmund Unsgård,et al.  Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. , 2012, JAMA.

[25]  Hobson Rw nd.  CREST (Carotid Revascularization Endarterectomy versus Stent Trial): background, design, and current status. , 2000 .

[26]  A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit , 2017, Scientific Reports.

[27]  A. Brodbelt,et al.  Diagnostic challenges, management and outcomes of midline low-grade gliomas , 2014, Journal of Neuro-Oncology.

[28]  Hilla Peretz,et al.  The , 1966 .

[29]  A. F. Adams,et al.  The Survey , 2021, Dyslexia in Higher Education.

[30]  M. Piérart,et al.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial , 2005, The Lancet.

[31]  K. Aldape,et al.  IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. , 2014, Neuro-oncology.

[32]  J. Raizer.  Faculty Opinions recommendation of CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. , 2018 .

[33]  M. Hassel,et al.  Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. , 2016, The Lancet. Oncology.

[34]  J. Sloan.  Asking the obvious questions regarding patient burden. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Cusimano,et al.  Considerations for a surgical RCT for diffuse low-grade glioma: a survey. , 2019, Neuro-oncology practice.

[36]  [World Health Organization classification of tumours of the central nervous system: a summary]. , 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[37]  Susan M. Chang,et al.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Hugues Duffau,et al.  Selection of intraoperative tasks for awake mapping based on relationships between tumor location and functional networks. , 2013, Journal of neurosurgery.

[39]  J. Sneep,et al.  With a summary , 1945 .

[40]  Elsa D. Angelini,et al.  Evidence for potentials and limitations of brain plasticity using an atlas of functional resectability of WHO grade II gliomas: Towards a “minimal common brain” , 2011, NeuroImage.

[41]  Gao Chen,et al.  Relationship between the extent of resection and the survival of patients with low-grade gliomas: a systematic review and meta-analysis , 2018, BMC Cancer.

[42]  Brigitta G. Baumert,et al.  Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma , 2016, The Lancet. Oncology.

[43]  M. Berger,et al.  Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  W. Stummer,et al.  Management of Patients With Low-Grade Gliomas – A Survey Among German Neurosurgical Departments , 2011, Central European neurosurgery.

[45]  D. Kondziolka,et al.  Randomized controlled trials and neurosurgery: the ideal fit or should alternative methodologies be considered? , 2016, Journal of neurosurgery.

[46]  Walter J. Curran,et al.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. , 2016, The New England journal of medicine.

[47]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.

[48]  F. Schmidt.  Meta-Analysis , 2008 .

[49]  A. Karim,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  S. Torp,et al.  Surgical resection versus watchful waiting in low-grade gliomas , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[52]  M. Weller,et al.  Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. , 2016, Neuro-oncology.

[53]  Adam A. Margolin,et al.  Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer , 2013, Science Translational Medicine.

[54]  S Hellman,et al.  Of mice but not men. Problems of the randomized clinical trial. , 1991, The New England journal of medicine.

[55]  H. Duffau,et al.  New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach. , 2014, Neuro-oncology.

[56]  A. Falini,et al.  Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps , 2016, European Radiology.

[57]  S. Pocock,et al.  An Extension of the CONSORT Statement , 2006 .

[58]  E. Emanuel,et al.  Patient Demands and Requests for Cancer Tests and Treatments. , 2015, JAMA oncology.

[59]  Adam Waldman,et al.  Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. , 2009, European journal of radiology.

[60]  H. Sebastian Seung,et al.  Learning the parts of objects by non-negative matrix factorization , 1999, Nature.

[61]  Jason A. Chen,et al.  Artificial Intelligence in the Management of Glioma: Era of Personalized Medicine , 2019, Front. Oncol..

[62]  G. Guyatt,et al.  Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. , 2007, Journal of clinical epidemiology.

[63]  C. Yeh,et al.  Focused Ultrasound-Induced Blood-Brain Barrier Opening: Association with Mechanical Index and Cavitation Index Analyzed by Dynamic Contrast-Enhanced Magnetic-Resonance Imaging , 2016, Scientific Reports.

[64]  M. Chicoine,et al.  Initial Experience Using Intraoperative Magnetic Resonance Imaging During a Trans-Sulcal Tubular Retractor Approach for the Resection of Deep-Seated Brain Tumors: A Case Series. , 2018, Operative neurosurgery.

[65]  H. Duffau.  Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up , 2015, Acta Neurochirurgica.

[66]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[67]  Steven D Chang,et al.  Biopsy versus resection for the management of low-grade gliomas. , 2017, The Cochrane database of systematic reviews.

[68]  R. Hobson,et al.  CREST (Carotid Revascularization Endarterectomy versus Stent Trial): background, design, and current status. , 2000, Seminars in vascular surgery.

[69]  Jenni A. M. Sidey-Gibbons,et al.  Machine learning in medicine: a practical introduction , 2019, BMC Medical Research Methodology.

[70]  K Subramonian,et al.  The ‘learning curve’ in surgery: what is it, how do we measure it and can we influence it? , 2004, BJU international.

[71]  Mitchel S Berger,et al.  Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. , 2011, Journal of neurosurgery.

[72]  Y. Lui,et al.  State of the Art: Machine Learning Applications in Glioma Imaging. , 2019, AJR. American journal of roentgenology.

[73]  G. Reifenberger,et al.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.

[74]  N. Black.  Why we need observational studies to evaluate the effectiveness of health care , 1996, BMJ.